Research and publish the best content.
Get Started for FREE
Sign up with Facebook Sign up with X
I don't have a Facebook or a X account
Already have an account: Login
Immunopathology & Immunotherapy
10.4K views |
+0 today
Latest advances in immunopathology diagnosis and treatment
Curated by
Alfredo Corell
 Your new post is loading...
Your new post is loading...
Scoop.it!
Cellular Immunology
Volume 280, Issue 1, November 2012, Pages 16–21 Shiying Shaoa, 1,Fan Heb, 1,Yan Yanga,Gang Yuana,Muxun Zhanga,Xuefeng Yua, , a Division of Endocrinology, Tongji Hospital, Tongji Medical College of Huazhong University of Science & Technology, Wuhan, PR Chinab Division of Nephrology, Tongji Hospital, Tongji Medical College of Huazhong University of Science & Technology, Wuhan, PR Chinahttp://dx.doi.org/10.1016/j.cellimm.2012.11.001,
Alfredo Corell's insight:
► This review firstly summarizes Th17 mediated immunology mechanism for T1D. ► We thoroughly introduce the characteristics of Th17 cells. ► Better understanding of mechanisms helps to develop treatment strategies for T1D. 
|
Scoop.it!
Alfredo Corell's insight:
Melbourne researchers have identified an immune protein that has the potential to stop or reverse the development of type 1 diabetes in its early stages, before insulin-producing cells have been destroyed.
video by Prof. Len Harrison (Walter+Eliza Hall) http://www.youtube.com/watch?feature=player_embedded&v=IwtphdQL6co
Scoop.it!
Increased Risk of Diabetes Mellitus and Likelihood of Receiving Diabetes Mellitus Treatment in Patients With Psoriasis Rahat S. Azfar, MD; Nicole M. Seminara, MD; Daniel B. Shin, BA; Andrea B. Troxel, ScD; David J. Margolis, MD, PhD; Joel M. Gelfand, MD, MSCE Arch Dermatol. 2012;148(9):995. doi:10.1001/archdermatol.2012.1401
Objective To assess the risk of incident diabetes mellitus (DM) in patients with psoriasis and to evaluate DM treatment patterns among patients with psoriasis and incident DM. Design Population-based cohort study. Setting United Kingdom–based electronic medical records. Patients We matched 108 132 patients with psoriasis aged 18 to 90 years with 430 716 unexposed patients based on practice and time of visit. For our nested study, only patients who developed incident DM during our study time were included. Main Outcome Measures Incident DM and adjusted risk of pharmacotherapy among those with incident DM. Results The fully adjusted hazard ratios (95% CIs) for incident DM were 1.14 (95% CI, 1.10-1.18), 1.11 (95% CI, 1.07-1.15), and 1.46 (95% CI, 1.30-1.65) in the overall, mild, and severe psoriasis groups, respectively. Among those with incident DM and severe psoriasis, the adjusted risk for receiving DM pharmacotherapy was 1.55 (95% CI, 1.15-2.10). Conclusions Our results suggest that psoriasis is an independent risk factor for the development of type 2 DM in a dose-dependent manner, and that patients with severe psoriasis who develop DM are more likely to receive systemic diabetic therapies in comparison with patients with DM but without psoriasis.
The finding in the news: http://www.webmd.com/skin-problems-and-treatments/psoriasis/news/20120829/psoriasis-linked-diabetes
http://www.emaxhealth.com/1275/psoriasis-and-type-2-diabetes-whats-connection
In spanish: http://www.elmundo.es/elmundosalud/2012/10/23/pielsana/1351013633.html
|
Including Immunology (pathology and therapies) topics: